RemeGen was cofounded in 2008 by Mr. Weidong Wang, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China, and Dr. Jianmin Fang, a Canadian-American scientist. Headquartered in the coastal city of Yantai, Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology and ophthalmic diseases.

Our mission is to discover, develop, produce and commercialize first-in-class and best-in-class biological drugs for autoimmune, oncology, ophthalmology, and other major diseases, to create clinical value, meet the major unmet clinical needs of the world, and maximize the value of the company.

Our vision is to become a leading world-class bio-pharmaceutical company in both China and the world.

Executive Director

Weidong Wang

Executive Director and Chairman of the Board

Jianmin Fang

Executive Director, Chief Executive Officer and Chief Scientific Officer

Ruyi He

Executive Director, Chief Medical Officer and Head of Clinical Research

Jian Lin

Executive Director

Non-Executive Director

Liqiang Wang

Non-Executive Director

Xiaodi Su

Non-Executive Director

Independent Non-Executive Director

Shanshan Yu

Non-Executive Director

Xianjing Hao

Non-Executive Director

Lan Ma

Non-Executive Director

We have also established our Scientific Advisory Board which currently comprises five renowned professors and key opinion leaders in the areas of our research and development, including Dr. Pei Gang, Dr. Fang Jianmin, Dr. He Ruyi, Dr. Marsha A. Moses and Dr. Lorne Babiuk.

See the Details

Members of our Scientific Advisory Board routinely meet or communicate with us and provide us with advisory services, including

  • Advice in respect of our business strategies and objectives
  • Academic updates and technical insights relevant to our research and development plans
  • Recommendations relating to innovative drug targets, mechanisms and modalities
  • Advice on new drug discovery projects
  • Biopharmaceutical market data and intelligence
Twitter Facebook 微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1